Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LM716 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LJM716 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LM716 | DRUG | - |
Inclusion Criteria: 1. Patients with the following indications: i) (Dose escalation part only): HER2 overexpressing locally advanced/ metastatic breast cancer or gastric cancer for which no effective treatment option exists: * For breast cancer: documented 3+ by immunohistochemistry, or ampl...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
LM716 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed as a potential oncology therapy for patients with advanced solid tumors.
LM716 is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the safety and efficacy of LM716 in patients with cancer.
LM716 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The Phase 1 study was designed to evaluate the safety, tolerability, and pharmacokinetics of LM716 in patients with advanced solid tumors.
LM716 has been studied in one clinical trial with the identifier NCT01911936. This was a Phase 1 study conducted in Japanese patients with advanced solid tumors. The trial has been completed and enrolled a total of 12 participants.
Yes, LM716 is also known as LJM716. The clinical trial NCT01911936, titled 'A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors,' refers to the same drug. Both names are used interchangeably in clinical research.